BioPharma Dive August 23, 2024
Bicara Therapeutics and Zenas BioPharma both registered plans for initial public offerings on Thursday.
Dive Brief:
- A pair of U.S. biotechnology companies on Thursday filed plans for initial public offerings, testing a market that’s proven challenging to crack for young drug startups lacking clinical data or without the backing of a major investor syndicate.
- One of the two, Zenas BioPharma, is developing a bifunctional monoclonal antibody called obexelimab for several immune diseases. Its most advanced program is in what’s known as immunoglobulin G4-related disease, for which it’s enrolling a Phase 3 trial testing the drug.
- Hot on its heels is Bicara Therapeutics, a cancer drugmaker in Phase 1 testing with a bifunctional antibody called ficerafusp alfa, which it’s developing...
Today's Sponsors
Today's Sponsor